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Abstract
Background Although the national HIV control pro-
gramme in Uganda has a well-established system for
monitoring disease progression and treatment outcomes,
monitoring of adverse drug reactions (ADRs) is inade-
quate. In order to address under-reporting of ADRs, the
National Pharmacovigilance Centre, in collaboration with
the HIV control programme, piloted a targeted spontaneous
reporting (TSR) system as a complementary method to
traditional spontaneous reporting.
Methods From April 2012 to March 2014, all cases of
suspected renal toxicity in 10,225 patients on tenofovir-based
regimens were monitored in the regional pharmacovigilance
centres of Masaka and Mbale. The identification of renal
toxicity was performed using serum creatinine, urinalysis,
and other signs and symptoms of kidney injury.
Results There was one suspected renal toxicity reported
for every 200 patients on a tenofovir-based regimen. Some
of the serious reactions reported were death in two cases
and bone demineralisation in five patients. Most of patients
had been on treatment for 2 years. Those that had been on
tenofovir for more than 4 years had raised serum creatinine
levels, emphasising the importance of monitoring for the
risk of renal damage for longer. We also found that the
reporting rate of suspected ADRs for all medicines in the
two sites increased almost fivefold during the implemen-
tation period.
Key Points
The targeted spontaneous reporting methodology can
increase reporting of suspected adverse reactions to a
drug.
Although the occurrence of renal toxicity associated
with tenofovir is low, in a resource-limited setting
where there is rapid scale-up of treatment and
patients are initiated on a tenofovir regimen without
initial screening, a monitoring programme for those
that may develop renal toxicity should be put in
place to encourage evidence-based decision making
for improved patient safety.
Having adopted and leveraged on existing structures
in the STD/AIDS Control Program, a platform for
collaboration with the National Pharmacovigilance
Centre was created, hence strengthening
pharmacovigilance activities.
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Conclusion Although the occurrence of suspected teno-
fovir renal toxicity of HIV patients is low, there is need to
monitor those at risk so as to prevent irreversible kidney
injury. TSR can complement spontaneous reporting for
collecting safety data on particular drugs and increase ADR
reporting rates.
1 Introduction
Uganda is a resource-limited country with a high disease
burden. Communicable diseases namely malaria, tubercu-
losis (TB) and HIV/AIDS account for 54 % of the total
burden of disease [1]. Access to essential medicines for
treating common diseases such as malaria, pneumonia,
HIV, and diabetes mellitus at facility level is reported at
50–68 % according to a survey conducted by the Ministry
of Health in 2008 [2]. In order to address the high disease
burden, the Ministry of Health is focused on rapidly ex-
panding access to essential medicines through implemen-
tation of public health programmes and targeting the major
communicable and non-communicable diseases. This in-
creased access to medicines is expected to increase the
number of people at risk of developing adverse drug re-
actions (ADRs).
The World Health Organization (WHO) Programme for
International Drug Monitoring, recognises a reporting rate
of over 200 suspected ADRs per million inhabitants/year,
sent at least once a quarter from a national pharma-
covigilance centre as good performance [3]. With more
than 10 million Individual Case Safety Reports (ICSR)
submitted from member countries of this WHO program-
me, VigiBase is one of the sources of international safety
data [4]. Analysis of the spontaneous reports in VigiBase
over a decade between the year 2000 and 2009 revealed
that high-income countries had high reporting rates ranging
from between 3 and 613 reports per million inhabitants per
year while low-income countries had the lowest range at
0–21 [5]. Despite recognition of the occurrence and burden
of ADRs and the need to report them, several studies show
that there is widespread under-reporting of ADRs to
spontaneous reporting systems, including serious or severe
ADRs [6–9]. The 2014 reporting rate from Uganda in
VigiBase corresponds to 20 reports per million in-
habitants [10, 11]. A study conducted to assess pharma-
covigilance systems in sub-Saharan Africa indicated that in
Uganda, public health programmes do not routinely collect
and share ADR data with the National Pharmacovigilance
Centre (NPC) [12].
As of September 2013, the national STD/AIDS Control
Program (ACP) had distributed antiretroviral (ARV)
medicines to over 570,573 HIV-infected persons [13]. The
HIV/AIDS 2013 Progress Report [13] showed that cotri-
moxazole was dispensed to over 800,000 persons living
with HIV whether ARV active or naive. Although, this
program has a well-established system for monitoring HIV
prevalence, incidence, numbers on treatment and treatment
outcomes, monitoring of ADRs due to ARVs is still
inadequate.
In order to address under-reporting of ADRs due to
ARVs, the NPC, in collaboration with the national ACP
piloted the targeted spontaneous reporting (TSR) approach
as a complementary method to the traditional spontaneous
reporting method. TSR (sometimes called stimulated re-
porting) is a variant of spontaneous reporting that focuses
on capturing ADRs in a well-defined group of patients on
treatment [14]. The WHO developed this TSR method-
ology in 2010 in three countries including Uganda with
support from the Monitoring Medicines Project under the
seventh framework programme (FP-7) of the European
Commission. Following a training workshop on this new
methodology, Uganda adapted TSR to monitor renal toxi-
city among HIV patients on tenofovir-based regimens. TSR
was the method chosen because it held the promise of a
comprehensive monitoring method that was affordable and
feasible in healthcare settings with limited human and fi-
nancial resources. TSR was considered likely to build on
the gains that had already been achieved by the existing
efforts in promoting the role of pharmacovigilance as a best
practice that improves the quality of care.
Although tenofovir had formerly been recommended as
part of the alternative first-line ARV therapy (ART) regi-
men in the national guidelines and is now the preferred
first-line regimen, little was known about its toxicity profile
in the Ugandan population. Several studies on the use of
tenofovir by patients with mild renal dysfunction or for
longer durations indicated that it might be associated with
renal toxicity [15–18]. In vitro studies also suggested a
higher risk than has been observed in patients [19]. Patient
populations are heterogeneous and treatment is compli-
cated by the coadministration of tenofovir with other drugs
that may enhance renal toxicity. Monitoring patients on a
tenofovir-based regimen for a possible increased risk of
renal dysfunction is therefore crucial. However, this is not
always done due to a lack of laboratory facilities, inade-
quate knowledge for monitoring and work overload,
especially in resource-limited settings. Failure to monitor
patients to identify those who may be at risk of developing
renal toxicity may result in significant deterioration in
kidney function over a number of years as well as other
complications.
The TSR method was adapted and piloted in the ACP
among patients on tenofovir-based ART regimens seeking
care from the two regional pharmacovigilance centres of
Masaka and Mbale Regional Referral hospitals and their
396 H. Ndagije et al.
catchment health facilities. The purpose of this study was
to pilot TSR using the example of renal toxicity to teno-




This was a pilot using TSR methodology to capture ADRs
for HIV-positive clients who were initiated on tenofovir-
based regimens. The Uganda health delivery system is
comprised of the following levels:
• national referral
• regional referral
• district or general hospital
• health centre IV (Serves a county, should be able to
admit patients having a senior medical officer and
another doctor as well as a theatre for carrying out
emergency operations)
• health centre III (Found in sub-county, runs an out-
patient clinic, treating common diseases and offering
antenatal care. Its led by a senior clinical officer and has
a functioning laboratory)
• health centre II (serves a few thousand people, led by a
registered nurse, runs an out-patient clinic treating
common diseases and offering antenatal care)
• health centre I (structured as village health teams and
working as a link between the community and the
health facilities).
Health services are also provided in the private sector
by for-profit health providers, not-for-profit healthcare
facilities and traditional/complimentary medicine provi-
ders. As of June 2014, the Ministry of Health had ac-
credited 1,572 public and private health facilities
countrywide to offer ART services. The health workers
involved in ART service delivery range from doctors,
clinical officers, registered nurses and midwives to nursing
assistants. The NPC has leveraged on the expertise in the
national and regional referral hospitals and has designated
these as regional pharmacovigilance centres. Two focal
persons were appointed by the hospitals to coordinate
activities in the region including the lower public health
facilities.
2.2 Site Selection
From April 2012 to March 2014, all cases of suspected
renal toxicity in patients on tenofovir-based regimens were
monitored in the two regional pharmacovigilance centres
of Masaka and Mbale. The population in the study sites had
been estimated at about 20,000 HIV-positive patients on
ART.
2.3 Monitoring of the Tenofovir-Based Regimen
For the pilot study, cases of suspected renal toxicity in
patients on tenofovir-based regimens were targeted and
monitored. Health workers in the pilot facilities were
trained to monitor for signs and symptoms of tenofovir
renal toxicity in all patients that were initiating or were
already on tenofovir-based regimens. The laboratory tests
carried out were serum creatinine and urinalysis (including
proteinuria and glycosuria) as per the recommendations in
the national guidelines for monitoring tenofovir at the
various levels of health service delivery [20–22]. The 2014
national ART guidelines recommend carrying out uri-
nalysis for monitoring of patients initiated on ART at
baseline and thereafter every 6 months or as required [20].
They further recommend carrying out serum creatinine
and/or blood urea to monitor renal function for patients on
tenofovir every 6 months at district and regional referral
hospitals.
The measurement parameters were the basis for the case
definition and any patient that presented with any one out-
of-range parameter was considered for suspected renal
toxicity. To simplify monitoring of patients at the pilot
sites, a job aid was developed to guide health workers on
the frequency of carrying out laboratory tests and on how
to identify and report suspected cases. Signs and symptoms
suggesting renal toxicity were described in the job aid (see
Electronic Supplementary Material 1). Changes from the
baseline parameters even in the absence of cardinal
symptoms of renal insufficiency would trigger adverse re-
action reporting.
2.4 Training and Support Supervision for the Targeted
Spontaneous Reporting (TSR) Methodology
The health professionals managing patients were trained on
the TSR methodology and renal toxicity monitoring as well
as any other safety concerns. To supplement the training,
support supervision was conducted regularly and involved
personnel from both the NPC and the ACP. During support
supervision, review meetings with the pharmacovigilance
centre focal persons were held and strategies for strength-
ening pharmacovigilance in the hospitals were reviewed.
Mentoring in ART care with focal facility personnel was
also done.
2.5 Data Collection
Based on the case definition and the national guidelines,
health workers reported suspected ADRs using the national
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form (see Electronic Supplementary Material 2). Com-
pleted reports were then relayed to the regional pharma-
covigilance coordinator who entered them into the web-
based case management system VigiFlowTM [23]. The
NPC staff and the ACP focal person held regular meetings
to assess causal relationships. The assessors assigned a
score to the components and factors considered in estab-
lishing the causal relationships between tenofovirand the
adverse events such as temporal sequence, alternative
causes, confirmation by objective evidence and challenge
and re-challenge with the drug. Each question was an-
swered positive (yes), negative (no), or unknown or inap-
plicable (do not know).The likelihood of tenofovir being
related to renal toxicity was assessed using the Naranjo
algorithm [24]. The suspected ADR was then assigned to a
category from the total score as follows: definite C9,
probable 5–8, possible 1–4, doubtful B0. A descriptive
summary of data on renal toxicity was created and is pre-
sented in Sect. 3.3.
2.6 Ethical Considerations
ADR monitoring and reporting is a routine clinical care
activity. Health workers were required to report the reac-
tions that they observe and those reported by the patients.
Informed consent was not individually taken from each
patient as the ADR form is confidential and was treated as
such by the NPC. Ethical clearance was sought from the
Uganda National Council for Science and Technology
(Ref: HS 1136), which provides ethics research clearance
at the national level in accordance to the World Medical
Association Helsinki Declaration. Approval for the pilot
was obtained from National Drug Authority and the ACP
to conduct this pilot study.
3 Results
3.1 Background to the Sites
A total of 10,225 patients were on tenofovir-based regi-
mens in the two pilot sites in the 24 months of the pilot
implementation. A majority of these patients were from the
Masaka region as presented in Table 1.
3.2 Demographics of the Suspected Renal Toxicity
Cases
Fifty-three (0.52 % of the exposed cases) of the suspected
renal toxicities were reported to the NPC, of which 23
(43.4 %) were males. The median age of these patients was
43 years [interquartile range (IQR) 33–51] and the median
body weight was 55 kg (IQR 47–62). Patients had been on
tenofovir-based regimen for a median duration of
24 months (IQR 12–36). All patients that had been on a
tenofovir regimen for more than 4 years had raised crea-
tinine levels.
The majority (60 %) of this cohort of patients were on the
tenofovir/lamivudine/nevirapine (TDF/3TC/NVP) combi-
nation, while 35 % were on tenofovir/lamivudine/efavirenz
(TDF/3TC/EFV) and the remaining 5 % were on the riton-
avir-boosted lopinavir in combination with TDF/3TC.
3.3 Presenting Signs and Symptoms for the Suspected
Renal Toxicity
Of the 53 cases with suspected renal toxicities, six (11 %)
presented with bilateral pedal oedema, four with facial
Table 1 Patients on the tenofovir-based regimen among the study
sites
Study site Number of patients
on tenofovir
Masaka Region
Masaka Regional Referral hospital 2,637
TASO Masaka 1,759
Villa Maria hospital 1,700
Lyantonde hospital 740
Kalungu Health Centre IV 63
Kitovu hospital 40
Bukulula Health Centre IV 348
Subtotal 7,287
Mbale Region
Mbale Regional Referral hospital 950
TASO Tororo 1,615










Increased creatinine ([1.2 g/dL) 43 (81) 53
Creatinine clearance[90 mL/min 43 (100) 43
Creatinine levels not provided 10 (19) 53
Proteinuria 25 (66) 38
Glycosuria and proteinuria 11 (44) 25
Bone demineralisation 5 (9) 53
Bilateral pitting pedal oedema 6 (11) 53
Facial puffiness 4 (8) 53
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puffiness and five with bone demineralisation, which was
confirmed by X-ray. Eleven (21 %) cases had out-of-range
urinalysis, and the results are summarised in Table 2 along
with other observed signs and symptoms of suspected renal
toxicity. All of the patients that presented with glycosuria
also had proteinuria. Two out of every three patients on a
tenofovir-based regimen whose protein levels were tested
(n = 38) had a positive result. Haematuria found in one
patient out of the 53 reported cases was not expected. None
of the patients in this study presented with hyperglycaemia.
Twenty-one patients were changed to a non-tenofovir-
based regimen and their urine parameters and creatinine
clearance improved thereafter. Tenofovir was substituted
with zidovudine in six of these cases and the other 15 cases
were substituted with abacavir. Two of those cases changed
to abacavir had co-morbidities of both hypertension and
diabetes, whereas two of the cases changed to zidovudine
also had hypertension. A 45-year-old male, who had been
on a tenofovir-based regimen for 5 years and presented
with increased serum creatinine, glycosuria and protein-
uria, was the only case with hypertension that was mon-
itored without a regimen change as the signs and symptoms
of renal damage resolved thereafter. Other co-morbidities
reported included one case of lipodystrophy and one case
of Kaposi’s sarcoma. The laboratory findings for one case
were consistent with Fanconi syndrome (i.e. hypouri-
caemia, hypokalaemia, generalised aminoaciduria and
proteinuria).
About 80 % of the cases tested had a raised serum
creatinine level. A raised serum creatinine and calculated
creatinine clearance of\90 mL/min (calculated with the
Cockroft and Gault formula) was reported in all 43 patients
that had a serum creatinine test performed and this is
presented in detail in Table 3.
One in every five cases of suspected renal toxicity did
not have a result for serum creatinine. The characteristics
of the ten patients whose serum creatinine results could not
be established are listed in Table 4. Six of the ten cases had
their regimen changed, mainly because of bone deminer-
alisation, and two patients died.
3.4 Causality Assessment
The majority (80 %) of the suspected renal toxicity cases
were classified as probable and the rest were possibly re-
lated to tenofovir. None of the causality assessment grading
belonged to the extreme categories of doubtful and definite.
3.5 Reporting Trends for Suspected Adverse Drug
Reactions
During the time of the pilot, there was an increase in the
overall number of ADR reports that VigiBase submitted to
the national pharmacovigilance system compared with the
previous years (shown in Fig. 1) and also specifically from
the annual number of reports collected in the two study sites
of Mbale and Masaka (seen in Table 5 with comparisons
before and after the TSR pilot period). The reports collected
is about five times more than the pre-study period.
4 Discussion
4.1 Background to the Study
This pilot was implemented to establish the feasibility and
positive effects that may accrue from a targeted sponta-
neous reporting methodology in resource-limited settings.
In the ACP, the TSR was adapted to monitor the safety of
patients on HIV treatment by focusing on suspected renal
toxicity related to the use of tenofovir.
4.2 Summary of Findings
In our study, there was one suspected renal toxicity re-
ported in every 200 patients on a tenofovir-based regimen.
Among the serious reactions reported were the death of two
patients and bone demineralisation, also known as osteo-
malacia, which occurred in five patients. Further assess-
ment of the causality relationship revealed that these
reports were probably or possibly but not definitely related
to tenofovir. The median duration of treatment for the
patients in this cohort was 2 years. However, all 13
(100 %) patients that had been on the tenofovir regimen for
more than 4 years had raised creatinine levels. This group
of patients emphasises the importance of monitoring for the
risk of renal damage the longer patients are on tenofovir.
We also found out that the reporting rate of suspected
ADRs to all medicines in the two selected sites increased
almost five-fold during the implementation of the TSR
methodology.
4.3 Suspected Adverse Reactions Associated
with Tenofovir
Tenofovir is a drug that is widely used for treatment of HIV
infections in Uganda as more than half of the patients on
ART in the two targeted study sites had it as part of their
regimen [20].
Based on the case definition, the findings from this pilot
support the presenting signs and symptoms of renal toxicity
associated with tenofovir that are not different from that
reported in the literature [16, 17]. According to the
manufacturer, adverse reactions with a suspected relation-
ship with tenofovir are classified as either uncommon (C1/
1,000 to \1/100) or rare (C1/10,000 to \1/1,000) [25].
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Increased serum creatinine was uncommon and renal fail-
ure, osteomalacia, lipodystrophy and angioedema were
considered to be rare in the European Summary of Product
Characteristics.
From our cases, proteinuria, glycosuria, raised serum
creatinine and bone demineralisation are characteristics of
tenofovir-induced kidney injury. Use of proteinuria and
glycosuria to screen for tenofovir-induced kidney injury
seems to be a very useful approach that should be em-
phasised and for which cost effectiveness ought to be
studied further, especially for long-term monitoring of
patients in resource-limited settings. Patients who had
proteinuria diagnosed with dipstick, their regimens subse-
quently changed had a positive treatment outcome similar
to other studies [16].
Since the main target for tenofovir toxicity is the
proximal tubule, the presence of tubular proteinuria would
be the most sensitive test for detecting proximal tubular
dysfunction. However, it was not possible to measure
tubular proteinuria in this pilot. The dipstick analysis used
in this pilot primarily detected albuminuria, which is in-
sensitive for low molecular weight proteinuria character-
istic of tenofovir toxicity. The alternative tests for assessing
proximal tubular function were to measure fractional ex-
cretion of phosphates and glycosuria, which are also
established markers of proximal tubule dysfunction and are
easy to screen for but are less sensitive tests than tubular
protein excretion. Glycosuria was found in 11 of the pa-
tients, who also had proteinuria, while bone demineral-
ization was found in five patients, which points to proximal
tubular dysfunction [16, 25, 26].
In studies [27, 28], serum creatinine[1.2 g/dL with
calculated creatinine clearance\90 mL/min was reported
in more than 80 % of the cases. This is consistent with
findings of a study of more than 1,000 HIV-infected pa-
tients on tenofovir which identified 1 % whose serum
creatinine increased to[120 g/dL [29]. The SCOLTA
(Surveillance Cohort Long-Term Toxicity Antiretroviral)
study of 754 HIV-infected, tenofovir-treated patients found
a 2.5 % incidence of creatinine elevations more than 1.5
times the upper limit of normal in a mean follow-up of
19.5 months, similar to the monitoring period of the pa-
tients in this pilot [29].
4.4 Achievement of the TSR Pilot
The project piloted TSR as a methodology for enhancing
ADR reporting in the ACP in Uganda. It was specifically
targeting patients who developed renal toxicity after taking
tenofovir. This initiative was the first of its kind in Uganda
and in sub-Saharan Africa.
The pilot was established on the basis of collaboration
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ensured ownership and division of activities according to
the comparative advantage of each participating entity. The
healthcare providers identified with the activity mostly
because of the involvement of the ACP.
As a result of this collaboration, the ACP incorporated
ADR reporting in its training manuals for ART. Also,
pharmacovigilance reports from ART sites are incorporat-
ed into the national quarterly ART report. This has in-
creased the number of spontaneous reports from public
health facilities. It has increased visibility of the NPC ac-
tivities by opening communication lines with all public
health system programmes through sharing of reports,
feedback meetings, case review meetings and joint training
of healthcare providers.
The pilot was observational with no exclusion and in-
clusion criteria for those monitored. Patients were mon-
itored in the routine clinical setting where risk factors and
gaps in care were observed and studied. In the case of
lifelong treatment such as ART, reporting lasts a lifetime as
well [14]. The fivefold increase in the reporting rate
compared to the pre-study period suggests that the TSR
methodology addresses the problem of under-reporting that
is seen with the traditional Ugandan spontaneous reporting.
Through joint support supervision activities, the NDA
and NPC were able to identify gaps in health service
provision. The point in case is the Ministry of Health ART
guidelines which were not clear to health workers regard-
ing monitoring patients on tenofovir. The NPC noted that
health workers were opting for more expensive tests such
as serum creatinine for monitoring tenofovir instead of a
urine dipstick which is a cheaper alternative.
This pilot had a capacity-building component in terms of
training, mentorship and feedback on the quality of care
provided at the health facilities. This motivated health
workers to provide better services and also to report sus-
pected adverse reactions. At the pilot close-out dis-
semination meeting, stakeholders were particularly
impressed by the feedback presented to them about the
quality of reports as analysed by the NPC. Stakeholders
requested that the TSR method of monitoring safety be
rolled out to other parts of the country.
4.5 Challenges and Limitations of the TSR Pilot
HIV treatment is a rapidly evolving field whose guidelines
keep changing. The recommendations for ART and pre-
venting mother to child transmission (PMTCT) kept
changing as the policies and guidelines changed. As a re-
sult, the planned TSR roll-out for PMTCT services has not
yet been carried out.
Table 5 Comparison of
suspected adverse drug reaction
reports collected from the study




Source of reports Period
Before TSR pilot study After start of TSR
2010 2011 Total 2012 2013 2014 Total
Study sites 17 27 44 142 46 181 369
Uganda VigiBase reports 60 518 578 42 239 687 968
Percentage 8 % (44/578) 38 % (369/968)
Fig. 1 Number of individual
case safety reports (ICSRs)
from Uganda in VigiBase per
year
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Assessment of the cases was difficult because some re-
ports did not have baseline tests for renal function at the
start of therapy. The dipstick analysis used in this pilot
detected primarily albuminuria and is insensitive for low
molecular weight proteinuria characteristic of tenofovir
toxicity. Ideally, proteinuria should be assessed by formal
measurement of the urine protein-to-creatinine ratio (P:C)
or albumin-to-creatinine ratio (A:C). This was not possible
in this study because the pilot used dipstick testing for
detecting proteinuria and hence absolute urine protein
values were not obtained. The lack of baseline laboratory
tests in some reported cases makes it difficult to attribute
the findings to tenofovir renal toxicity since it was not
possible to rule out the existence of renal disease before
tenofovir regimens had been started.
Monitoring for ADRs was initially viewed as an extra
activity stretching the programme’s logistics and resources.
The NPC at one point provided some supplies and gave
incentives to those involved in the project. Health workers
viewed the programme as research that comes with added
work since they already have a heavy workload from their
usual work and so expected allowances. The joint support
supervision encouraged the health workers and contributed
to their change of attitude and the quality of patient care
started improving.
4.6 Recommendations
Use of targeted surveillance monitoring strategies increases
the number of reports and can help to identify risks that are
associated with specific treatment in public health pro-
grammes. This plays an important role in signal detection.
The role of co-morbidities such as hypertension and dia-
betes in this case also needs to be further studied as the
TSR is rolled out. The numbers in this study were too small
to come to a meaningful conclusion regarding their rela-
tionship to tenofovir-associated renal toxicity. The cost
effectiveness of using these simple tests should also be
further studied, especially in resource-limited settings.
Pharmacovigilance should be integrated into public
health systems as a routine activity. However, there is still
the need to plan for pharmacovigilance activities and re-
sources such as having a focal person at the health facility
level, especially where there are high patient loads, and a
regional focal person to coordinate pharmacovigilance
activities within the regions. In order to improve ADR
reporting, the reporting of pharmacovigilance activities in
Uganda needs to be simplified and harmonised with the
current electronic reporting systems for the public health
programmes and the health management information sys-
tems. Advocacy for integration should be enhanced by the
relevant stakeholders and continuous information sharing.
For successful implementation, involvement of different
stakeholders is key because the issues encountered are
better handled by a multi-disciplinary approach.
5 Conclusion
This pilot revealed that the incidence of suspected adverse
events that are possibly related to the use of tenofovir-
based regimens in HIV treatment is one report in 200 pa-
tients. We also found that the reporting rate of suspected
ADRs to all medicines in the two selected sites increased
almost fivefold during the implementation of the TSR
methodology.
Targeted spontaneous reporting as a surveillance
method can complement spontaneous reporting since it
comes with the advantages of an increased reporting rate
and the possibility of calculating the incidence of the ADR
in question. In resource-limited settings, a successful
monitoring programme for the safety of medicines used in
public health programmes can be implemented and a
specific question of interest can be answered in a specific
population. This encourages use of evidence-based deci-
sion making for a better-quality patient care programme.
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